🧫
Nrf2 inhibitor ML385 mechanism validation experiment
active
experiment
Created: 2026-04-10T22:49:03
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-25159d1d-2d48-4bb0-bfb1-c59b93dd4dbc
🧫 Experiment Protocol
Exploratorysepsis-associated acute lung injuryNrf2RAW264.7 cells and/or mouse modelproposed
This experiment used ML385, a specific Nrf2 inhibitor, to validate that acteoside's anti-ferroptotic effects are mediated through Nrf2 activation. The study involved treating cells with acteoside in the presence of ML385 to demonstrate that blocking Nrf2 signaling would prevent acteoside's protective effects against ferroptosis. This pharmacological approach provided direct evidence that the Nrf2 pathway is essential for acteoside's mechanism of action. The experiment confirmed that acteoside's anti-ferroptotic and protective effects in SALI depend on Nrf2 activation, establishing a clear mechanistic link between the compound, the transcription factor, and the cellular death pathway.
PRIMARY OUTCOME
blocking of acteoside's anti-ferroptotic action
EXPECTED OUTCOMES
ML385 blocks acteoside's anti-ferroptotic effects
SUCCESS CRITERIA
loss of acteoside's anti-ferroptotic activity when Nrf2 is inhibited
PROTOCOL
co-treatment with acteoside and ML385, assessment of ferroptosis markers
LINKED HYPOTHESES
Source: PMID 41895086 ↗
🧫 Experiment Extras
PATHWAY
Nrf2 signaling, ferroptosis pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.